Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

-- Poster to be presented at American College of Rheumatology Convergence 2025 –

BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that new data from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), a novel gene therapy candidate for osteoarthritis of the knee, will be presented at the American College of Rheumatology (ACR) Convergence 2025 meeting, taking place from October 24-29 in Chicago, Il.

Read more at globenewswire.com